Mental Stress Ischemia: Biofeedback Study

Coronary Artery Disease Clinical Trial

— MIBS  

Official title:

Effects of Biofeedback on Myocardial Blood Flow Changes During Mental Stress in Patients With Coronary Artery Disease

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02657382
• Other study ID #: IRB00083616
• Status: Completed
• Phase: N/A
• Start date: September 2015
• Est. completion date: June 24, 2020

Study information

• Verified date: September 2020
• Source: Emory University
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to evaluate the blood flow to the heart during stress and assess changes in blood flow after psychological treatment in participants with coronary artery disease. The aims of the study are to assess the effects of heart rate variability (HRV) biofeedback (versus usual care) on global and regional myocardial blood flow (MBF), peripheral vascular function, and autonomic changes during mental stress.

Description:

The purpose of this study is to evaluate the blood flow to the heart during stress and assess changes in blood flow after psychological treatment in participants with coronary artery disease. This is a randomized controlled study. The aims of the study are to assess the effects of heart rate variability (HRV) biofeedback (versus usual care) on global and regional myocardial blood flow (MBF), peripheral vascular function, and autonomic changes during mental stress.

All participants will undergo myocardial flow/perfusion imaging with positron emission tomography (PET) imaging at rest and after a standardized arithmetic mental stress test. Participants will then undergo repeat testing after 6 weeks. At 12 weeks, participants will also undergo a limited examination without myocardial perfusion imaging. The intervention group will receive biofeedback after enrollment, and the wait-list control group will receive the intervention between week 6 and week 12 study visits (without imaging).

Recruitment information / eligibility

• Status: Completed
• Enrollment: 25
• Est. completion date: June 24, 2020
• Est. primary completion date: June 24, 2020
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

Prior participation in the Mental Stress Ischemia: Mechanisms and Prognosis (MIPS) study

Eligibility for the MIPS study included:

• Angiographically proven disease including at least 1 major vessel with evidence of disease but with no specific minimum lumen diameter criteria

• Prior myocardial ischemia (MI) (>1 months) documented by typical elevation of enzymes and typical pain or ECG changes

• Abnormal coronary intravascular ultrasound exam (IVUS) demonstrating atherosclerosis of at least 1 vessel

• Post bypass surgery or post PCI (percutaneous intervention)* (> 1 year after complete revascularization)

• Positive nuclear scan or stress exercise test

Exclusion Criteria:

• Unstable angina, myocardial infarction, decompensated congestive heart failure in past week

• Severe concomitant medical problems expected to shorten life expectancy to less than 5 years

• Pregnancy. Women of childbearing age who are not postmenopausal will be screened by pregnancy test

• Systolic blood pressure >190 mm Hg or diastolic blood pressure >115 mm Hg on the day of the test

• History of current alcohol or substance abuse or dependence (past year); or history of severe psychiatric disorder other than major depression, such as schizophrenia or psychotic depression

• For patients who are unable to exercise, we will do a pharmacological stress test with regadenoson. Additional exclusion criteria for regadenoson administration include second- or third-degree AV block (without permanent pacemakers) and bronchospastic disease such as asthma or severe chronic obstructive lung disease

• Weight more than 450 lbs or a body habitus that is unfit for the nuclear camera dimensions

• Inflammatory diseases - Rheumatoid Arthritis, Lupus, Hepatitis, HIV, Crohn's, etc.

• Dialysis

• Any malignancy (No active/any metastasis from oncology notes)

• Dementia/Alzheimer's

• Drug incompliance

• No supporting documents for CAD history

• Permanent atrial fibrillation

• Clean vessels after revascularization

• Any transplants

• On any immunosuppressants

• Immobile, in wheel chair (If patient can lift self out of wheel chair then it is okay)

Related Conditions & MeSH terms

• Cardiovascular Disease
• Cardiovascular Diseases
• Coronary Artery Disease
• Coronary Disease
• Myocardial Ischemia
• Stress, Psychological

Intervention

Behavioral:
• Heart Rate Variability (HRV) Biofeedback (BF)
Heart Rate Variability (HRV) biofeedback involves deep breathing, mindfulness (focusing on one's emotions and thoughts) and cognitive therapy (identifying and changing unhelpful or inaccurate thinking and distressing emotional responses). It is a 6-week training with one hour sessions with a certified biofeedback coach once per week. A handheld personal stress reliever device will be provided to the patients to practice at home for 20 minutes a day.

Other:
• Mental Stress Protocol
Mental stress will consist of a 3-min math serial subtraction paradigm.The participants will be asked to serially subtract 7 from number specified by the researcher. For participants who have difficulty with this task, easier serial subtraction will be provided for. Throughout the task, to increase stressfulness and titrate difficulty, the participant will be prompted for faster performance and the starting number from which they were subtracting will be periodically changed. Finally, to add an evaluation component, participants will be given negative feedback during the test.

Locations

Country	Name	City	State
United States	Emory University	Atlanta	Georgia
United States	Emory University Hospital	Atlanta	Georgia
United States	Rollins School of Public Health	Atlanta	Georgia
United States	The Emory Clinic	Atlanta	Georgia

Sponsors (1)

Lead Sponsor	Collaborator
Emory University

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Change in Global Myocardial Perfusion During Mental Stress	Global myocardial perfusion during mental stress will be tested via positron emission topography (PET) scan while completing the mental stress protocol.	Baseline, Week 6
Primary	Change in Regional Myocardial Perfusion During Mental Stress	Regional myocardial perfusion during mental stress will be tested via positron emission topography (PET) scan while completing the mental stress protocol.	Baseline, Week 6
Secondary	Change in Arterial Compliance assessed by Augmentation Index and Pulse Wave Velocity	Arterial compliance will be assessed using the SphygmaCor device which is a non-invasive method for assessing the cardiovascular system focused on central blood pressures, measures of arterial stiffness and autonomic function. Peripheral pressure waveforms are recorded from the radial artery at the wrist, using applanation tonometry with a high-fidelity micromanometer. After 20 sequential waveforms have been acquired, a validated generalized transfer function will be used to generate the corresponding central aortic pressure waveform.	Baseline, Week 12
Secondary	Change in Number of Ischemic Regions	Number of ischemic regions will be measured by PET scan myocardial infusion. Change is defined as the difference in the number of ischemic regions from baseline compared to week six.	Baseline, Week 6
Secondary	Change in Peripheral Arterial Tonometry (PAT) Ratio	The Peripheral Arterial Tonometry (PAT) reflects the magnitude of change in finger-tip blood flow induced by mental stress by measuring the ratio of pulse wave amplitude during mental stress compared to rest.	Baseline, Week 12
Secondary	Change in Resting Norepinephrine Levels	Change in resting norepinephrine levels post mental stress test will be evaluated via blood draws obtained at baseline, immediately post mental stress testing, and 90 minutes post mental stress testing. Testing will be completed at all study visits. Change is measured as the difference between resting norepinephrine levels at baseline and post intervention.	Baseline, Post Intervention (Up to 12 weeks)
Secondary	Change in Resting Epinephrine Levels	Change in resting epinephrine levels post mental stress test will be evaluated via blood draws obtained at baseline, immediately post mental stress testing, and 90 minutes post mental stress testing. Testing will be completed at all study visits. Change is measured as the difference between resting epinephrine levels at baseline and post intervention.	Baseline, Post Intervention (Up to 12 weeks)
Secondary	Change in Resting Dopamine Levels	Change in resting dopamine levels post mental stress test will be evaluated via blood draws obtained at baseline, immediately post mental stress testing, and 90 minutes post mental stress testing. Testing will be completed at all study visits. Change is measured as the difference between resting dopamine levels at baseline and post intervention.	Baseline, Post Intervention (Up to 12 weeks)
Secondary	Change in Flow-Mediated Dilation (FMD) of the Brachial Artery	Two-dimensional ultrasound images will be used to assess flow-mediated dilation (FMD) of the brachial artery before and 30 minutes after mental stress testing. Images will be obtained with an Acuson 10 mHz linear array transducer and an Acuson Aspen ultrasound system. Change is measured as the difference in FMD at baseline and week 12.	Baseline, Week 12